The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Thiazolidinedione Treatment Normalizes Insulin Resistance and Ischemic Injury in the Zucker Fatty Rat Heart
Open accessAbstract
Obesity is associated with risk factors for cardiovascular disease, including insulin resistance, and can lead to cardiac hypertrophy and congestive heart failure. Here, we used the insulin-sensitizing agent rosiglitazone to investigate the cellular mechanisms linking insulin resistance in the obese Zucker rat heart with increased susceptibility to ischemic injury. Rats were treated for 7 or 14 days with 3 mg/kg per os rosiglitazone. Hearts were isolated and perfused before and during insulin stimulation or during 32 min low-flow ischemia at 0.3 ml · min−1 · grams wet wt−1 and reperfusion. d[2-3H]glucose was used as a tracer of glucose uptake, and phosphorus-31 nuclear magnetic resonance spectroscopy was used to follow energetics during ischemia. At 12 months of age, obese rat hearts were insulin resistant with decreased GLUT4 protein expression. During ischemia, glucose uptake was lower and depletion of ATP was greater in obese rat hearts, thereby significantly impairing recovery of contractile function during reperfusion. Rosiglitazone treatment normalized the insulin resistance and restored GLUT4 protein levels in obese rat hearts. Glucose uptake during ischemia was also normalized by rosiglitazone treatment, thereby preventing the greater loss of ATP and restoring recovery of contractile function to that of lean rat hearts. We conclude that rosiglitazone treatment, by normalizing glucose uptake, protected obese rat hearts from ischemic injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, studies in older Zucker rats demonstrated reduced recovery from ischemia, which could be prevented by treating these animals with a TZD (159, 322, 389).”
From Cardiac remodeling in obesity (2008) · cites this paper as [322]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM
Boden, G. (1997) · Diabetes · doi:10.2337/diab.46.1.3 · Cited by 1,728
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Lipotoxic heart disease in obese rats: Implications for human obesity
Zhou, Y.-T., Grayburn, P., Karim, A., Shimabukuro, M., Higa, M., Baetens, D., Orci, L., & Unger, R. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1784 · Cited by 1,265
Vidal‐Puig, A., Considine, R. V., Jimenez‐Liñan, M., Werman, A., Pories, W. J., Caro, J. F., & Flier, J. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119424 · Cited by 785
Friedman, J. M. (2000) · Nature · doi:10.1038/35007504 · Cited by 709
Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists
Olefsky, J. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10843 · Cited by 536
Goodyear, L. J., Giorgino, F., Sherman, L., Carey, J., Smith, R. J., & Dohm, G. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117909 · Cited by 527
Cited by
Sorted by citations
Items 101–164 of 164
Bhandari, U., Kumar, V., Kumar, P., Tripathi, C., & Khanna, G. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.171290 · Cited by 24
Sasaki, H., Ogawa, K., Shimizu, M., Mori, C., Takatsuka, H., Okazaki, F., Kawai, M., Taniguchi, I., & Mochizuki, S. (2007) · International Heart Journal · doi:10.1536/ihj.48.623 · Cited by 24
Dandona, P., Ghanim, H., Chaudhuri, A., & Mohanty, P. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.10.009 · Cited by 23
Pioglitazone induces de novo ceramide synthesis in the rat heart
Baranowski, M., Błachnio-Zabielska, A. U., Zabielski, P., & Górski, J. (2006) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2006.10.004 · Cited by 23
van den Brom, C. E., Bulte, C. S. E., Loer, S. A., Bouwman, R. A., & Boer, C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-42 · Cited by 24
Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism
Karlstaedt, A., Schiffer, W. B., & Taegtmeyer, H. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00071 · Cited by 21
Trivedi, M. V., Marwaha, A., & Lokhandwala, M. F. (2004) · Hypertension · doi:10.1161/01.hyp.0000111587.51185.fe · Cited by 20
Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice?
Hemmeryckx, B., Hoylaerts, M., Gallacher, D. J., Lu, H. R., Himmelreich, U., D’hooge, J., Swinnen, M., & Lijnen, H. R. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.062 · Cited by 19
Gonsolin, D., Couturier, K., Garait, B., Rondel, S., Novel-Chaté, V., Peltier, S., Faure, P., Gachon, P., Boirie, Y., Kériel, C., et al. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9291-7 · Cited by 19
Insulin resistance and the effects of thiazolidinediones on cardiac metabolism
Young, L. H. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.013 · Cited by 19
Obesity and Preclinical Changes of Cardiac Geometry and Function
Sung, J. K., & Kim, J. (2010) · Korean Circulation Journal · doi:10.4070/kcj.2010.40.2.55 · Cited by 18
Apaijai, N., Chattipakorn, S. C., & Chattipakorn, N. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6553-6 · Cited by 18
Ooie, T., Kajimoto, M., Takahashi, N., Shinohara, T., Taniguchi, Y., Kouno, H., Wakisaka, O., Yoshimatsu, H., & Saikawa, T. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.12.034 · Cited by 18
Kamel, M. A. E.-N. (2014) · International Journal of Biochemistry Research & Review · doi:10.9734/ijbcrr/2014/10649 · Cited by 18
Goltsman, I., Wang, X., LaVallie, E. R., DiBlasio-Smith, E. A., Ovcharenko, E., Hoffman, A., Abassi, Z. A., Feuerstein, G., & Winaver, J. M. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.960179 · Cited by 17
Myocardial Insulin Resistance: An Overview of Its Causes, Effects, and Potential Therapy
Toit, E. F. D., & Donner, D. G. (2012) · InTech eBooks · doi:10.5772/50619 · Cited by 18
Emerging therapy strategies for energy metabolism in acute myocardial infarction
Ma, R., Lu, D., Yang, Z., Ji, X., Tian, R., Xu, F., Chen, Y., & Li, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07088-9 · Cited by 16
Handzlik, M. K., Constantin‐Teodosiu, D., Greenhaff, P. L., & Cole, M. A. (2018) · The Journal of Physiology · doi:10.1113/jp275357 · Cited by 16
Self-citationWang, X., Liu, X., Zhan, Y., LaVallie, E. R., Diblasio-Smith, L., Collins‐Racie, L. A., Mounts, W. M., Rutkowski, J. L., Xu, X. S., Goltsman, I., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167635 · Cited by 15
Abou‐Daya, K. I., Daya, H. A., Nassereddine, M., Nahhas, G. J., & Nuwayri‐Salti, N. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12140 · Cited by 14
Polycystic Ovarian Syndrome: the Next Cardiovascular Dilemma in Women?
Srikanthan, P., Korenman, S. G., & Davis, S. S. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.05.001 · Cited by 14
Romero‐Nava, R., Zhou, D., Garcı́a, N., Ruíz-Hernández, A., Yin-chu, S., Sánchez‐Muñoz, F., Huang, F., Hong, E., & Villafaña, S. (2017) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2017.1298133 · Cited by 13
Tomczyk, M., Braczko, A., Mierzejewska, P., Podlacha, M., Król, O., Jabłońska, P., Jędrzejewska, A., Pierzynowska, K., Węgrzyn, G., Slominska, E. M., et al. (2022) · Cells · doi:10.3390/cells11172662 · Cited by 13
Kurian, G. A., & Paddikkala, J. (2010) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(10)60043-0 · Cited by 13
Impaired peripheral glucose sensing in F1 offspring of diabetic pregnancy
Kamel, M. A. E.-N., Helmy, M. H., Hanafi, M. Y., Mahmoud, S. A., & Elfetooh, H. A. (2014) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-014-0338-z · Cited by 12
Thackeray, J. T., deKemp, R. A., Beanlands, R. S., & DaSilva, J. N. (2014) · Journal of Nuclear Cardiology · doi:10.1007/s12350-014-9900-x · Cited by 12
Huang, J. V., Li, L., Ye, S., Bergman, B. C., Sparagna, G. C., Sarraf, M., Reusch, J. E. B., Greyson, C. R., & Schwartz, G. G. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00535.2012 · Cited by 12
Intracellular pH Regulates TRAIL-Induced Apoptosis and Necroptosis in Endothelial Cells
Zhang, Z., Gan, I., Pavlosky, A., Huang, X., Fuhrmann, B., & Jevnikar, A. M. (2017) · Journal of Immunology Research · doi:10.1155/2017/1503960 · Cited by 11
Wilder, C. D. E., Masoud, R., Yazar, D., O’Brien, B. A., Eykyn, T. R., & Curtis, M. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13332 · Cited by 9
Prevention of nutritionally induced diabetes by rosiglitazone in the gerbil Psammomys obesus
Hefetz, S., Ziv, E., Jörns, A., Lenzen, S., & Shafrir, E. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.583 · Cited by 9
Effects of excess salt and fat intake on myocardial function and infarct size in rat
Mozaffari, M. S., Patel, C., Ballas, C., & Schaffer, S. W. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.08.014 · Cited by 9
Lipotoxicity in Diabetic Cardiomyopathy: Molecular Basis and Emerging Therapeutic Targets
Han, Y., Chen, X., Fonseka, O., & Liu, W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062740 · Cited by 7
Trolle, C., Hjerrild, B., Mortensen, K. H., Knorr, S., Søndergaard, H. M., Christiansen, J. S., & Gravholt, C. H. (2015) · Clinical Endocrinology · doi:10.1111/cen.12720 · Cited by 7
The Failing Heart: Is It an Inefficient Engine or an Engine Out of Fuel?
Masoud, W. G. T., Clanachan, A. S., & Lopaschuk, G. D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-5930-9_4 · Cited by 7
Anzawa, R., Seki, S., Horikoshi, K., Taniguchi, M., & Mochizuki, S. (2007) · Cardiovascular Diabetology · doi:10.1186/1475-2840-6-17 · Cited by 6
Jaswal, J. S., Cadete, V. J. J., & Lopaschuk, G. D. (2008) · Heart and Metabolism · Cited by 5
Amin, S., Azam, F., Nabi, S., Khan, M. A., Abdullah, A., Shaquiquzzaman, M., Iqubal, A., Akhter, M., Tasneem, S., Khanna, S., et al. (2025) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.70021 · Cited by 4
Metabolic perturbations in the diabetic heart: Mechanisms and molecular targets
Abel, E. D. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.04.002 · Cited by 4
Myoung, K.-S., Ahn, Y., Lee, M.-H., Park, D.-Y., Ahn, Y.-M., & Huh, C. (2013) · Journal of the Korean Society of Food Science and Nutrition · doi:10.3746/jkfn.2013.42.1.026 · Cited by 4
Cardiomyopathy of Insulin Resistance
Witteles, R. M., & Fowler, M. B. (2006) · Heart Failure Clinics · doi:10.1016/j.hfc.2005.11.007 · Cited by 4
Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002
Anker, S. D., Jankowska, E. A., & Okonko, D. O. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.5.639 · Cited by 4
Nuclear Receptors and the Adaptive Response of the Heart
Parry, T. L., Ledee, D. R., Willis, M. S., & Portman, M. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803111-7.00010-5 · Cited by 5
Dietary fat and insulin resistance: a connection through leptin and PPARγ activation
Al-Jada, D. N., & Ahmad, M. N. (2016) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v6i6.249 · Cited by 3
PPARγ Agonists and Vascular Risk Factors: Potential Effects on Cardiovascular Disease
Asnani, S., Theuma, P., & Fonseca, V. A. (2003) · Metabolic Syndrome and Related Disorders · doi:10.1089/154041903321648234 · Cited by 3
Drexler, A., Nesto, R. W., Abrahamson, M. J., Bakris, G. L., Bell, D. S. H., Brunzell, J. D., Dandona, P., Davidson, J. A., Fonseca, V. A., Fowler, M. B., et al. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.147 · Cited by 3
Molecular Changes in Fatty Acid Oxidation in the Failing Heart
Jaswal, J. S., Keung, W., Wang, W., Ussher, J. R., & Lopaschuk, G. D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7130-2_12 · Cited by 2
PPARs and Myocardial Response to Ischemia in Normal and Diseased Heart
Ravingerová, T., Adameová, A., Čarnická, S., Kelly, T., Nemčeková, M., Matejíková, J., & Lazou, A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7207-1_14 · Cited by 1
CARDIAC DYSFUNCTION IN THE ZDF RAT: POSSIBLE MECHANISMS AND BENEFITS OF EXERCISE
VanHoose, L. (2011) · KU ScholarWorks (The University of Kansas) · Cited by 1
Peroxisome proliferator activated receptors, inflammation, the vasculature and the heart
Diep, Q., Amiri, F., & Schiffrin, E. (2003) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8047-3_20
Nduhirabandi, F. (2014) · SUNScholar (Stellenbosch University)
Insulin Resistance and Acute Cardiovascular Complications
Tack, C. J. (2003) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/108925320300700115
Smith, W. T. (2012) · SUNScholar (Stellenbosch University)
Diabetes and Cardiac Mitochondria
Marı́n-Garcı́a, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4599-9_20
Obesity and Cardiac Dysfunction
Sweeney, G., Litwin, S. E., & Abel, E. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1607-5_14
Tissue Repair and Cancer Control through PPARs and Their Coregulators
Michalik, L., & Wahli, W. (2008) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812819178_0013
Vitiello, D., Couturier, K., & Dubouchaud, H. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000614
Alrob, O. A. (2018) · Jordan Journal of Pharmaceutical Sciences
Donner, D. G. (2015) · Griffith Research Online · doi:10.13140/rg.2.1.1191.1761
Metabolic efficiency in remodeled failing hearts
Masoud, W. G. T. (2015) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r39s1ks1s
D’Souza, A. (2011) · CLOK (University of Central Lancashire)
Fourny, N. (2019) · theses.fr (ABES) · doi:10.70675/846aa6e5z8362z45a5z8e8dz2452913634b4
Cardioprotection à la phase aiguë de l'infarctus
Ghaboura, N. (2010) · OpenGrey (Institut de l'Information Scientifique et Technique)
Metadata
- Authors
- Sidell, R. J., Cole, M. A., Draper, N. J., Desrois, M., Buckingham, R. E., & Clarke, K.
- Affiliations
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2002-04-01
- Volume
- 51
- Issue
- 4
- Pages
- 1110-1117
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2166216264
- Cited by
- 165
- References
- 50
- Citations by year
- 2026: 1 · 2025: 2 · 2022: 1 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 6 · 2016: 5 · 2015: 9 · 2014: 8 · 2013: 9 · 2012: 8
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- British Heart Foundation (PS/02/002/14893)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- rosiglitazone, thiazolidinediones, insulin resistance, obesity, Zucker fatty rats, myocardial ischemia, myocardial ischemia-reperfusion injury, GLUT4, glucose uptake, cardiac contractile function, cardiac hypertrophy, congestive heart failure
- MeSH terms
- Rosiglitazone, Animals, Blood Glucose, Blood Pressure, Body Weight, Heart, Heart Rate, Hypoglycemic Agents, Insulin Resistance, Obesity, Organ Size, Perfusion, Rats, Zucker, Reference Values, Thiazoles, Time Factors, Myocardial Reperfusion, Myocardial Ischemia, Thiazolidinediones, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
